Story perspectives

Political opposition stalls U.S. anti-progestin breast cancer trials

By Drooid · Sep 23, 2026, 3:33 AM UTC · How we work

Summary

Story summary

U.S. researchers claim anti-progestin drugs could dramatically cut breast cancer rates, yet political opposition stalls U.S. studies.
Dr. Laura Esserman of UCSF says mifepristone is approved, safe, and could cut cases from 325,000 to 150,000.
European researchers will push anti-progestin trials with government support as U.S. funding stays uncertain.
Dr. Sacha Howell says U.S. replication is now extremely hard because of a hostile political climate.

1 of 1

Story summary

U.S. researchers claim anti-progestin drugs could dramatically cut breast cancer rates, yet political opposition stalls U.S. studies.
Dr. Laura Esserman of UCSF says mifepristone is approved, safe, and could cut cases from 325,000 to 150,000.
European researchers will push anti-progestin trials with government support as U.S. funding stays uncertain.
Dr. Sacha Howell says U.S. replication is now extremely hard because of a hostile political climate.